Variables | Missing, n | All | Women | Men | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Cohort 1 | Cohort 2 | p | Cohort 1 | Cohort 2 | p | Cohort 1 | Cohort 2 | p | ||
n | 928 | 1010 | 632 | 706 | 296 | 304 | ||||
Age, yrs | 0 | 53 (14) | 56 (15) | < 0.001 | 52 (14) | 55 (15) | < 0.001 | 57 (13) | 58 (14) | 0.235 |
Disease duration, mos | 0 | 6.3 (3.1) | 5.9 (3.1) | 0.004 | 6.4 (3.1) | 6.0 (3.1) | 0.005 | 5.9 (3.0) | 5.7 (3.1) | 0.315 |
Never smoker, % | 44 | 38 | 50 | 43 | 0.012 | 30 | 26 | 0.183 | ||
Smoker, % | 7 | 27 | 25 | 0.005 | 26 | 26 | 30 | 26 | ||
Previous smoker, % | 29 | 36 | 24 | 31 | 40 | 48 | ||||
RF-positive, % | 33 | 60 | 63 | 0.241 | 58 | 64 | 0.031 | 65 | 62 | 0.272 |
HAQ, 0–3 | 119 | 0.95 (0.60) | 1.02 (0.63) | 0.012 | 1.02 (0.60) | 1.08 (0.64) | 0.071 | 0.79 (0.56) | 0.88 (0.60) | 0.065 |
DAS28, 0–9.4 | 57 | 5.16 (1.21) | 5.35 (1.22) | 0.001 | 5.24 (1.17) | 5.38 (1.23) | 0.032 | 4.99 (1.29) | 5.26 (1.20) | 0.009 |
VAS pain, 0–100 mm | 48 | 44.8 (24.3) | 48.5 (24.1) | 0.001 | 46.1 (24.2) | 50.0 (23.8) | 0.004 | 41.9 (24.4) | 44.9 (24.5) | 0.134 |
PtGA, 0–100 mm | 36 | 44.5 (25.5) | 47.5 (25.8) | 0.003 | 45.7 (25.9) | 49.0 (25.5) | 0.020 | 40.4 (24.4) | 44.0 (26.2) | 0.087 |
SHS | 343 | 2.9 (7.1) | 4.9 (9.1) | < 0.001 | 2.7 (6.4) | 5.0 (9.4) | < 0.001 | 3.3 (8.5) | 4.5 (8.3) | 0.084 |
JSN | 343 | 2.1 (4.8) | 4.2 (7.4) | < 0.001 | 2.0 (4.6) | 4.4 (7.7) | < 0.001 | 2.2 (5.2) | 3.6 (6.7) | 0.008 |
ES | 343 | 1.6 (4.0) | 1.4 (3.2) | 0.248 | 1.4 (3.4) | 1.4 (3.3) | 0.936 | 2.1 (5.0) | 1.5 (3.2) | 0.109 |
Significant data are in bold face. RF: rheumatoid factor; HAQ: Health Assessment Questionnaire; DAS28: 28-joint Disease Activity Score; VAS: visual analog scale; PtGA: patient’s global assessment; SHS: van der Heijde modification of the Sharp score; JSN: joint space narrowing; ES: erosion score.